{"slug":"gene-cell-therapy","topic":"gene-cell-therapy","title":"Gene & Cell Therapy: State of the Field (October 2026)","summary":"Covers adeno-associated virus (AAV) and lentiviral gene therapy, in vivo CAR-T and stem-cell-derived replacement cells such as islets and dopaminergic neurons, with the evidence as of October 2026. The main takeaway: viral gene addition has clinical precedent in several monogenic diseases, but immune responses, dose-linked toxicity and integration questions still bound the field, while in vivo CAR-T and stem-cell replacement remain at early clinical or preclinical stages.","version":1,"published_at":"2026-10-30","updated_at":"2026-10-30","stats":{"words":3785,"citations":57,"claims":34,"timeline":19,"benchmarks":8,"open_problems":6,"key_papers":15,"glossary":16},"verification":{"status":"verified","method":"automated figure and citation-relevance triage against cited abstracts, plus targeted AI review with web checks of flagged statements; automated citation resolution","claims_checked":17,"issues_fixed":16,"verified_at":"2026-10-30"},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/gene-cell-therapy","preview_url":"https://space-kitty.com/api/v1/dossiers/gene-cell-therapy/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/gene-cell-therapy","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Adeno-associated virus (AAV) in vivo gene therapy","anchor":"adeno-associated-virus-aav-in-vivo-gene-therapy"},{"level":3,"text":"Capsid engineering and immune evasion","anchor":"capsid-engineering-and-immune-evasion"},{"level":3,"text":"Lentiviral and ex vivo HSPC gene therapy","anchor":"lentiviral-and-ex-vivo-hspc-gene-therapy"},{"level":3,"text":"In vivo CAR-T and CAR engineering","anchor":"in-vivo-car-t-and-car-engineering"},{"level":3,"text":"Stem-cell-derived islets","anchor":"stem-cell-derived-islets"},{"level":3,"text":"Dopaminergic cell replacement and gene correction","anchor":"dopaminergic-cell-replacement-and-gene-correction"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch (near term)","anchor":"outlook-what-to-watch-near-term"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["In a 2022 meta-analysis of 255 rAAV clinical trials, AAV2 was the most frequently used serotype (reported as 29.8%, n = 72 trials); the abstract does not state the denominator for this percentage.","The same meta-analysis reports 20 trials (reported as 8.3%) using engineered capsids; the abstract does not state the denominator."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":57,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/gene-cell-therapy with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}